R&D
We contribute to promoting human health.
We are the global leader in stem cell therapies
Immune cells : T cells, NK cells, dendritic cells, NKT cells
NK cells : preclinical completion, target disease: lung cancer
Immune cell banking : storage for 6 sessions with single blood collection (other hospitals take blood every session)
Diversification and optimization of treatment programs
NK cell
Dendritic cell
T cell
iNKT cell
Keycell-IM Inj. Is an anti-cancer immune cell therapy agent that is collected by autologous peripheral blood.
T cells, NK cells, iNKT cells, and dendritic cells separated by EHL Bio's specialized activation culture technology and then stored and frozen.
New ways of treating side effects and resistance problems of existing anti-cancer treatments
Removal of fine residual cancer, prevention of recurrence and metastasis
It can be administered up to 6-12 times with one blood draw, which improves the patient's quality of life with less physical burden
With apheresis equipment, it is possible to acquire 30 times more cell numbers than normal blood collection by collecting components
Unlike conventional treatment using single cells, a new method of treatment using multiple conjugated immune cells
New concept of complex anti-cancer treatment through maximization of effect by fusion administration of single culture for the first time in Korea
Unlike other companies, the number of cells to be administered is constant because each cell is cultured and administered according to the number of cells.
